Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4689 - Neutrophil-to-lymphocyte ratio in metastatic breast cancer: association with clinico-pathological features and outcome.


11 Sep 2017


Poster display session


Breast Cancer


Michele Bartoletti


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


M. Bartoletti1, L. Gerratana1, S. Zago2, D. Basile1, M.G. Vitale1, G. Pelizzari1, M. Bonotto1, C. Bozza1, V. Fanotto1, C. Lisanti1, M. Cinausero1, S. Barban1, M. Lera1, I. Venuti1, M. Mansutti3, A.M. Minisini3, G. Fasola3, F. Curcio2, F. Puglisi1

Author affiliations

  • 1 School Of Medical Oncology, Department Of Medicine, University of Udine, 33100 - Udine/IT
  • 2 Clinical Pathology Institute, University Hospital of Udine, 33100 - Udine/IT
  • 3 Department Of Oncology, University Hospital of Udine, 33100 - Udine/IT


Abstract 4689


Tumors are closely linked with systemic inflammation, of which neutrophil-to-lymphocyte ratio (NLR) represents a simple and inexpensive tool of evaluation. Previous data suggested that a high NLR is associated with poor prognosis in several tumors, including breast cancer (BC). However, few studies involved patients (pts) with metastatic breast cancer (mBC).


We retrospectively analyzed clinico-pathological features and treatment outcome of 595 consecutive mBC pts treated at the Department of Oncology of Udine, Italy, between 2004 and 2014. NLR was calculated from the blood count performed before first line therapy start. Differences in NLR according to clinico-pathological characteristics were investigated through chi-square test. Cox regression was used to determine the prognostic impact of NLR.


A statistically significant higher NLR was found in pts whose tumor had the following features: high grade (P = 0.009), ductal isotype (P = 0.02), ER negativity (P = 0.003), PgR negativity (P = 0.0001), high Ki-67 (P = 0.03). There were no statistical differences in NLR between HER2-positive and HER2-negative BC (P = 0.33). Among subtypes, triple-negative BC were associated with higher NLR, while luminal HER2+ BC with lower NLR (P = 0.004). No statistical differences in NLR were found according to visceral disease (P = 0.13) nor according with bone-only disease (P = 0.24). At univariate analysis, a NLR ≥2.64 was associated with worse progression-free survival after first line therapy (HR 1.41, 95%CI 1.11-1.79, P = 0.005) and with worse overall survival (HR 1.76, 95%CI 1.32-2.36, P 


High NLR was associated with pathological features of BC, but did not represent an independent prognostic factor at multivariate analysis. Further investigation is warranted to identify the appropriate cut-off value of NLR and the BC subtypes in which its prognostic role could be more useful.

Clinical trial identification

Legal entity responsible for the study

University of Udine




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.